Last Updated: August 10, 2026

Details for Patent: 11,234,985

Name: Drug Patent Intelligence for US Patent 11234985
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 11,234,985 protect, and when does it expire?

Patent 11,234,985 protects DOVATO and is included in one NDA.

This patent has one hundred and forty-five patent family members in forty-four countries.

Summary for Patent: 11,234,985

Title:	Antiviral therapy
Abstract:	The present invention relates to combinations of compounds comprising HIV integrase inhibitors and other therapeutic agents. Such combinations are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.
Inventor(s):	Mark Richard Underwood
Assignee:	ViiV Healthcare Co
Application Number:	US16/835,733
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,234,985
Patent Claim Types: see list of patent claims	Use; Composition;
Patent landscape, scope, and claims:	error: insufficient information More… ↓ ⤷ Start Trial

Drugs Protected by US Patent 11,234,985

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Viiv Hlthcare	DOVATO	dolutegravir sodium; lamivudine	TABLET;ORAL	211994-001	Apr 8, 2019		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y			TREATMENT OF HIV INFECTION	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 11,234,985

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2932970	⤷ Start Trial	CA 2018 00036	Denmark	⤷ Start Trial
European Patent Office	2932970	⤷ Start Trial	PA2018013	Lithuania	⤷ Start Trial
European Patent Office	2932970	⤷ Start Trial	300957	Netherlands	⤷ Start Trial
European Patent Office	2932970	⤷ Start Trial	122018000125	Germany	⤷ Start Trial
European Patent Office	2932970	⤷ Start Trial	2018C/041	Belgium	⤷ Start Trial
European Patent Office	2932970	⤷ Start Trial	LUC00090	Luxembourg	⤷ Start Trial
European Patent Office	2932970	⤷ Start Trial	CR 2018 00036	Denmark	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.